Life360 price target raised to $55 from $40 at JMP Securities
JMP Securities analyst Andrew Boone raised the firm’s price target on Life360 (LIF) to $55 from $40 and keeps an Outperform rating on the ...
TD Cowen Sticks to Its Buy Rating for Iovance Biotherapeutics (IOVA)
In a report released today, Tyler Van Buren from TD Cowen maintained a Buy rating on Iovance Biotherapeutics (IOVA – Research Report).